Agenus

Cash flows and milestones are inherently unpredictable. The FDA advised against accelerated approval, and Agenus discontinued financial support for its metastatic CRC Phase 3 after only three months to refocus on neoadjuvant colon cancer, resetting timelines.

Event‑driven endpoints, enrollment risk (850 patients planned), and competitive dynamics in colon cancer further reduce visibility. While translational analyses and multi‑tumor data are encouraging, the regulatory bar in MSS CRC is high given historic failures of checkpoint therapy in this population.